Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC

NCT05244213 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer
EGFR Activating Mutation

Interventions

BIOLOGICAL: Sintilimab
DRUG: Carboplatin
DRUG: Nab paclitaxel

Sponsor

Guangdong Provincial People's Hospital